Theriva Biologics, Inc.
TOVX
$0.25
$0.000.77%
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.17% | 21.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.76% | -14.48% | |||
| Operating Income | -54.91% | 25.05% | |||
| Income Before Tax | -57.39% | -2.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.39% | -2.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.39% | -2.40% | |||
| EBIT | -54.91% | 25.05% | |||
| EBITDA | -55.54% | 25.19% | |||
| EPS Basic | -40.76% | 58.43% | |||
| Normalized Basic EPS | -40.84% | 47.47% | |||
| EPS Diluted | -40.76% | 58.43% | |||
| Normalized Diluted EPS | -40.84% | 47.47% | |||
| Average Basic Shares Outstanding | 11.74% | 40.30% | |||
| Average Diluted Shares Outstanding | 11.74% | 40.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||